Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Michael Serzan MD

Michael T. Serzan MD

Medical Oncologist, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute; Instructor of Medicine, Harvard Medical School, Boston, Massachusetts

Dr. Michael Serzan is a Medical Oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute. He is an Instructor of Medicine at Harvard Medical School.

Dr. Serzan completed his undergraduate studies at Boston College before receiving his MD at Rutgers Robert Wood Johnson Medical School. He received Internal Medicine training and served as Chief Resident at Medstar Georgetown University Hospital. He received Hematology and Oncology fellowship training at the Georgetown Lombardi Comprehensive Cancer Center.

Dr. Serzan joined the Lank Center for Genitourinary Oncology in 2022 and has expertise in the treatment of patients with kidney, bladder, prostate, and testicular cancer.

Dr. Serzan has a research focus on the development of novel therapeutic agents and conduct of clinical trials for the treatment of advanced genitourinary malignancies.

Disclosures

None reported.

Recent Contributions to PracticeUpdate:

  1. Cabozantinib Plus Nivolumab and Ipilimumab for Renal Cell Carcinoma
  2. Temporary Treatment Cessation vs Continuation of First-Line TKIs in Patients With Advanced Clear Cell RCC

Recently Updated